AI assistant
Sending…
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021
Mar 16, 2021
31580_dirs_2021-03-16_0b31c3d5-2622-4f1b-afe7-aadcd30378dd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-03-01
Reporting Person: Miles Darrin (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-01 | Common stock | S | 2200 | $47.99 | Disposed | 11171 | Direct |
| 2021-03-05 | Common stock | S | 500 | $48.58 | Disposed | 10671 | Direct |
Footnotes
F1: Includes 314 shares purchased through the Company's employee stock purchase plan.
More from AGIOS PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
Apr 29
Earnings Release
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3